Menu
Oslo, March 26, 2026: Thor Medical, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, has entered into a multiyear frame agreement with Node Pharma, a Norwegian radiopharmaceutical company, for the supply of radium-224 (Ra-224) and lead-212 (Pb-212) for preclinical use.
The agreement follows successful product sample deliveries from Thor Medical’s pilot facility at Herøya Industrial Park to Node Pharma and supports further expansion of Node Pharma’s development pipeline for alpha-emitting therapies. Radium-224 and lead-212, together with thorium-228, are part of Thor Medical’s portfolio of products.
“The agreement is a further validation of our capabilities to deliver high-quality products from our facility at Herøya, but most importantly it confirms a market trend we have observed over time, namely the growing demand for isotopes such as radium-224 and lead-212. With Node Pharma as a partner, we are supporting an exciting development program while gaining valuable insight into future product needs,” said Jasper C. Kurth, CEO of Thor Medical.
“Reliable isotope supply is a critical enabler for our pipeline strategy. This agreement with Thor Medical broadens our access to key alpha-emitting isotopes and supports the continued expansion of our alpha pipeline,” said Erik Mjåland, Chief Business Officer and Co-founder of Node Pharma.
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'. To learn more, visit www.thormedical.com - http://www.thormedical.com.
ABOUT NODE PHARMA AS
Node Pharma is a radiopharmaceutical company developing first-in-class targeted alpha therapies for cancer patients with limited treatment options. Its lead asset, targeting liver cancer, is designed to be plug-and-play with existing clinical infrastructure and workflow, upgrading current approaches from beta to alpha radiation. Its isotope-agnostic platform supports expansion across multiple isotopes and indications. The company is chaired by Dr. Thomas Ramdahl, the first CEO of Algeta ASA, the company behind Xofigo® (Ra-223), which Bayer acquired for approximately US$2.9 bn in 2014.
CONTACTS
Thor Medical ASA
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, Thor Medical ASA, +47 988 05 724, mathias.reierth@thormedical.com
Node Pharma AS
Erik Mjåland, CBO & Co-founder, Node Pharma AS, +47 900 17 688, erik@nodepharma.no
